Search details
1.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Article
in English
| MEDLINE | ID: mdl-34246347
2.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34860318
3.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34264439
4.
Robust network inference using response logic.
Bioinformatics
; 35(14): i634-i642, 2019 07 15.
Article
in English
| MEDLINE | ID: mdl-31510692
5.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28800861
6.
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.
Lancet Oncol
; 18(11): e638, 2017 11.
Article
in English
| MEDLINE | ID: mdl-29208392
7.
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.
Nat Commun
; 14(1): 5945, 2023 09 23.
Article
in English
| MEDLINE | ID: mdl-37741832
8.
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Clin Cancer Res
; 28(5): 993-1003, 2022 Mar 01.
Article
in English
| MEDLINE | ID: mdl-34907082
9.
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Clin Cancer Res
; 27(4): 1162-1173, 2021 02 15.
Article
in English
| MEDLINE | ID: mdl-33023953
10.
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer.
JCO Precis Oncol
; 4: 1012-1024, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-35050767
11.
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation.
Cell Death Differ
; 26(11): 2416-2429, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-30824837
12.
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Nat Med
; 25(6): 929-935, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31171876
13.
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.
Clin Cancer Res
; 25(11): 3239-3246, 2019 06 01.
Article
in English
| MEDLINE | ID: mdl-30824584
14.
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Pigment Cell Melanoma Res
; 31(4): 516-522, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29156488
15.
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.
JCO Precis Oncol
; 2: 1-17, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-35135117
16.
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.
JCO Precis Oncol
; 2: 1-18, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-35135126
17.
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
Clin Cancer Res
; 23(17): 5238-5245, 2017 Sep 01.
Article
in English
| MEDLINE | ID: mdl-28536307
18.
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
Cancer Cell
; 29(4): 477-493, 2016 Apr 11.
Article
in English
| MEDLINE | ID: mdl-26996308
19.
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Cancer Chemother Pharmacol
; 71(5): 1315-23, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23468082
Results
1 -
19
de 19
1
Next >
>>